Skip to content
Menu
Network
Sub-Menu
Browse by Subject
Browse by Publisher
Join the Network
Get Started
Subscribe
Support
Contact
Search
Close
Enter Search Terms
Search
Michael Ellenberger
ID:
1b82610b-2619-30fb-68c4
/
Claimed Record
/
Organization:
Rothwell Figg
Published Works
13 articles
FDA Guidance, Clinical Pipelines, and the Emerging Deal Landscape of Psychedelic Therapeutics
RF EMerge ·
August 4, 2026
cite
Much Ado About “About”
Biosimilars Law Bulletin ·
May 14, 2026
cite
Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy – March 2026 Update
RF EMerge ·
March 5, 2026
cite
FDA Proposes Sweeping Changes to Accelerate Biosimilar Development
Biosimilars Law Bulletin ·
November 7, 2025
cite
Key IP Licensing Considerations for AI Drug Discovery Platforms
RF EMerge ·
October 17, 2025
cite
Previous
1
2
3
Next
Practice Areas
Health Care and Life Sciences
Business and Commercial
Jurisdictions
North America
United States
Washington, D.C.
